NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-07
Reading CABR? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CABR free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisThis stock is volatile — it swings about 4% on a typical day and fell roughly 84% in its worst 12-month stretch.
View RiskCABR's growth depends on the Healthcare sector improving to justify its current price. Recent performance has been weak, and there is no earnings yield to assess. CABR trades at an elevated risk level, with no standing thesis yet. If CABR misses earnings again, it could face continued pressure. Peer multiples imply a price about 12% above where it trades; this read is provisional.
Trailing returns as of 2026-07-07. CABR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
A consensus fair price across 0 valuation methods, at three horizons. Current price $1.39. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
